No black box warning on record for Temodar

As of the latest FDA labeling reviewed, Temodar (TEMOZOLOMIDE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Temodar medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Myelosuppression : Monitor absolute neutrophil count (ANC) and platelet count prior to each cycle and during treatment. Geriatric patients and women have a higher risk of developing myelosuppression. ( 5.1 , 8.5 ) Hepatotoxicity : Fatal and severe hepatotoxicity have been reported. Perform liver tests at baseline, midway through the first cycle, prior to each subsequent

No black box warning on record for Temodar

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Myelosuppression : Monitor absolute neutrophil count (ANC) and platelet count prior to each cycle and during treatment. Geriatric patients and women have a higher risk of developing myelosuppression. ( 5.1 , 8.5 ) Hepatotoxicity : Fatal and severe hepatotoxicity have been reported. Perform liver tests at baseline, midway through the first cycle, prior to each subsequent

Temodar Black Box Warning

No black box warning on record for Temodar

Other warnings & precautions

Temodar Black Box Warning

No black box warning on record for Temodar

Other warnings & precautions